

Flexible synthesis of isomeric pyranoindolones and evaluation of cytotoxicity towards HeLa cells

J C JEYAVEERAN^a, CHANDRASEKAR PRAVEEN^{b,*}, Y ARUN^c, A A M PRINCE^a
and P T PERUMAL^c

^aDepartment of Chemistry, Ramakrishna Mission Vivekananda College, Mylapore, Chennai 600 004, India

^bFunctional Materials Division, Central Electrochemical Research Institute (CSIR laboratory),
Karaikudi 630 006, India

^cOrganic Chemistry Division, Central Leather Research Institute (CSIR laboratory), Adyar,
Chennai 600 020, India

e-mail: chandrasekar.praveen@gmail.com

MS received 17 November 2015; revised 10 January 2016; accepted 6 March 2016

Abstract. A hybrid pharmacophore approach for the synthesis of isomeric pyranoindolones was achieved by employing gold(III) chloride-catalyzed cycloisomerization of alkyne-tethered indole carboxylic acids in good to excellent yield. All the synthesized compounds were evaluated for their tumor cell growth inhibitory activity against human cervix adenocarcinoma (HeLa) which revealed that three compounds exhibited activity comparable with the standard *cis*-platin ($IC_{50} = 0.08 \mu M$). Molecular docking of all the compounds in Vaccinia H1-Related (VHR) Phosphatase receptor also supported that compound **7d** as the most active with a free energy of binding as -8.27 kcal/mol.

Keywords. Pyranoindolones; positional isomers; gold catalysis; chemical synthesis; cytotoxicity; molecular docking.

1. Introduction

In recent years, homogeneous gold catalysis was frequently applied in medicinal chemistry for the synthesis of bioactive natural products and clinical drugs.¹ Ever since its first use in homogeneous gold catalysis, the catalytic application of AuCl₃ has been used in numerous organic transformations.² Our group was engaged in the development and applications of gold catalyzed methodologies for the synthesis of hetero- and carbocycles.^{3a–j} Towards this end, we have previously communicated the AuCl₃ catalyzed cycloisomerization of 3-alkynyl-indole-2-carboxylic acid leading to pyrano[3,4-*b*]indol-1(9*H*)-ones, which exhibited moderate cytotoxicity towards HeLa cells.^{3d} As a logical extension, we envisaged the synthesis of corresponding positional isomer, pyrano[4,3-*b*]indol-1(5*H*)-ones by utilising 2-alkynyl-indole-3-carboxylic acid instead of 3-alkynyl-indole-2-carboxylic acids (figure 1). At the outset, the success of such a deceptively simple variant could not be taken for granted, since these compounds may show improved levels of cytotoxicity. Surprisingly, the synthesis of these types of compounds has scarcely been investigated. Some rare examples

include [(Cp*RhCl₂)₂]/Cu(OAc)₂ catalyzed oxidative coupling of indole-3-carboxylic acid with internal alkynes,⁴ Pd(OAc)₂/AgCO₃ catalyzed annulation of allenes with indole-2-carboxylic acids,⁵ cycloisomerization of indole acetylenic acids by π -Lewis acid.^{3d,6} Given the significance of these methodologies, a catalytic protocol that accomplishes the general and flexible synthesis of isomeric pyranoindolones remains to be developed. In this context, we herein report the synthesis and cytotoxic evaluation of pyrano[4,3-*b*]indol-1(5*H*)-ones towards HeLa cells. The results of chemical synthesis as well as comparison of the biological data with our previously reported pyrano[3,4-*b*]indol-1(9*H*)-one scaffolds are disclosed in this paper.

2. Experimental

2.1 Materials and instruments

All commercially available solvents and reagents were used without further purification. Solutions in organic solvents were dried with anhydrous sodium sulphate. Solvents were evaporated under reduced pressure. Melting points were obtained using open capillaries and are uncorrected. Infrared (IR) spectra were recorded on

*For correspondence




Figure 1. Structures of isomeric pyranoindolones.

a Perkin-Elmer FTIR spectrophotometer as KBr pellets for solid compounds and neat sample for liquid compounds. ^1H and ^{13}C NMR spectra were obtained in $\text{DMSO-}d_6$ and CDCl_3 on a JEOL spectrometer at 500 and 125 MHz, respectively. Proton chemical shifts (δ) are relative to tetramethylsilane (TMS, $\delta = 0.00$) as internal standard and expressed in parts per million. The number of protons (n) for a given resonance was indicated as $n\text{H}$. Spin multiplicities are given as s (singlet), d (doublet), t (triplet), dd (doublet of doublet), dt (doublet of triplet), ddd (doublet of doublet of doublet) and m (multiplet). Coupling constants (J) are given in hertz. Elemental analyses were recorded using a Thermo Finnigan FLASH EA 1112CHN analyzer. All the compounds gave C, H and N analysis within $\pm 0.5\%$ of the theoretical values. Column chromatography was performed using a mixture of petroleum ether and ethyl acetate on silica gel (100–200 mesh, SRL, India). Analytical TLC was performed on precoated plastic sheets of silica gel G/UV-254 of 0.2 mm thickness (Macherey-Nagel, Germany) using analytical grade solvents and visualized with iodine spray (10% w/w I_2 in silica gel), UV light ($\lambda = 254$ and 365 nm) and alkaline KMnO_4 solution. Human cervical cancer cell line (HeLa) was obtained from National Centre for Cell Science (Pune, India). Cells were cultured in Dulbecco's modified Eagle medium (DMEM) (Sigma Chemical Co.) containing glucose (5 mM) and supplemented with 10% fetal bovine serum and maintained at 37°C in a humidified incubator with an atmosphere of 5% CO_2 . The in vitro cytotoxicity of the compounds was evaluated using MTT colourimetric assay. Absorbance (at λ_{max}) was read on Tenac 200 plate reader at 570 nm. The IC_{50} values were calculated using the PrismPad computer program (GraphPad Software, Inc., San Diego, CA) and were defined as concentration of drug causing 50% inhibition in absorbance compared with control (vehicle) cells. All computations for molecular docking studies were carried out on a Dell Desktop D510 personal computer (2.4 GHz Pentium 4 processor, Intel, Santa Clara, CA) running Red Hat Enterprise Linux Client release 5.5. The time required for each simulation run

was on the order of Real = 1 h 13 m 54.67 s, CPU = 1 h 08 m 54.57 s, System = 11.75 s on the Pentium machine.

2.2 Methods and Characterization

2.2a General Procedure for the esterification of indole-2-carboxylic acids **2a and **2b**:** To an ice-cold solution of indole-2-carboxylic acid (5.0 g) in methanol (60 mL) was added concentrated sulphuric acid (5 mL). The reaction mixture was refluxed for 24 h and concentrated under reduced pressure. To this reaction mixture was added ice-cold water (50 mL) and extracted with EtOAc (3×50 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated to afford analytically pure product (98% yield) which was used for the next step without further purification.

2.2b General procedure for the iodination of indole-2-carboxylic acid methyl ester **3a and **3b**:** To a solution of indole-2-carboxylic acid methyl ester (5.0 g) in 15 mL of DMF was added powdered KOH (3.0 equiv) and stirred for 15 min. To this mixture was added a solution of iodine (1.1 equiv) in DMF (15 mL) and stirred for 3 h. After completion of the reaction as indicated by TLC, the reaction mixture was quenched with 10% NaHSO_3 and extracted with EtOAc (3×30 mL). The EtOAc extract was repeatedly washed with 10% $\text{Na}_2\text{S}_2\text{O}_3$ and aqueous ammonia. The combined organic extract was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford the pure product (90% yield) which was used for the next step without further purification.

2.2c General procedure for the N-alkylation of 3-iodo-indole-2-carboxylic acid methyl ester **4a, **4b**, **4d** and **4e**:** To a mixture of NaH (2.0 equiv) in DMF (3 mL) kept at 0°C at N_2 atmosphere was added a solution of 3-iodo-indole-2-carboxylate (1.0 equiv) in DMF (2 mL) and stirred for 15 min. To this mixture was added the corresponding alkyl halide (1.2 equiv) and stirred for 3 h at 0°C to room temperature. After completion of the reaction as indicated by TLC, the reaction mixture was quenched with water and extracted with EtOAc (3×10 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, concentrated and purified by column chromatography on silica gel using petroleum ether/EtOAc to afford the pure product.

2.2c1 1-Methyl-3-iodo-1H-indole-2-carboxylic acid methyl ester (4a**):** 91% yield; Yellow solid; M.p. $64\text{--}65^\circ\text{C}$; IR (KBr): 2925, 2360, 1704, 1455, 1247, 1100, 741 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 3.97 (s, 3H);

4.05 (s, 3H); 7.22 (t, 1H, $J = 6.8$ Hz); 7.32 (d, 1H, $J = 8.4$ Hz); 7.39 (t, 1H, $J = 6.8$ Hz); 7.56 (d, 1H, $J = 7.6$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 33.1, 51.7, 110.5, 121.5, 124.0, 126.2, 128.8, 130.3, 130.4, 139.0, 161.9. GC-MS: $m/z = 315$ [M^+]. Anal. Calcd for $\text{C}_{11}\text{H}_{10}\text{INO}_2$: C, 41.93; H, 3.20; N, 4.45%. Found: C, 42.11; H, 3.16; N, 4.39%.

2.2c2 *1-Ethyl-3-iodo-1H-indole-2-carboxylic acid methyl ester (4b)*: 85% yield; Brown oil; IR (neat): 2928, 1706, 1465, 1218, 1110, 745 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 1.49 (t, 3H, $J = 6.9$ Hz); 3.97 (s, 3H); 4.45 (q, 2H, $J = 6.8$ Hz); 7.21 (t, 1H, $J = 6.8$ Hz); 7.34–7.37 (m, 2H); 7.56 (d, 1H, $J = 7.6$ Hz). ^{13}C NMR (125 MHz, CDCl_3): 15.8, 41.0, 51.7, 110.5, 121.5, 121.6, 124.1, 126.0, 126.1, 130.5, 138.0, 161.3. GC-MS: $m/z = 329$ [M^+]. Anal. Calcd for $\text{C}_{12}\text{H}_{12}\text{INO}_2$: C, 43.79; H, 3.67; N, 4.26%. Found: C, 43.89; H, 3.65; N, 4.24%.

2.2c3 *3-Iodo-5-methoxy-1-methyl-1H-indole-2-carboxylic acid methyl ester (4d)*: 92% yield; Yellow solid; M.p. 107–108°C; IR (KBr): 2900, 2360, 1692, 1446, 1218 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 3.89 (s, 3H); 3.96 (s, 3H); 4.01 (s, 3H); 6.91 (s, 1H); 7.02 (d, 1H, $J = 9.1$ Hz); 7.22 (d, 1H, $J = 9.1$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 32.2, 51.6, 55.8, 103.5, 111.7, 118.1, 128.6, 130.6, 134.4, 155.5, 161.8. GC-MS: $m/z = 345$ [M^+]. Anal. Calcd for $\text{C}_{12}\text{H}_{12}\text{INO}_3$: C, 41.76; H, 3.50; N, 4.06%. Found: C, 41.91; H, 3.46; N, 4.02%.

2.2c4 *3-Iodo-5-methoxy-1-ethyl-1H-indole-2-carboxylic acid methyl ester (4e)*: 83% yield; Brown oil; IR (neat): 2919, 1706, 1455, 1204, 830 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 1.47 (t, 3H, $J = 6.8$ Hz); 3.86 (s, 3H); 3.94 (s, 3H); 4.42 (q, 2H, $J = 7.6$ Hz); 6.90 (d, 1H, $J = 2.3$ Hz); 6.99 (d, 1H, $J = 8.4$ Hz); 7.19 (d, 1H, $J = 9.1$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 14.3, 41.1, 55.7, 61.2, 103.6, 111.6, 117.9, 118.0, 127.6, 130.7, 133.2, 155.5, 161.1. GC-MS: $m/z = 359$ [M^+]. Anal. Calcd for $\text{C}_{13}\text{H}_{14}\text{INO}_3$: C, 43.47; H, 3.93; N, 3.90%. Found: C, 43.21; H, 3.97; N, 3.96%.

2.2d *General procedure for the N-alkylation of 3-iodo-indole-2-carboxylic acid methyl ester 4c, 4f and 4g*: To a mixture of KOH (3.0 equiv) in DMSO (3 mL) kept at 0°C was added, 3-iodo-indole-2-carboxylate (1.0 equiv) and stirred for 30 min. To this mixture was added the corresponding alkyl halide (5.0 equiv) and stirred for 6 h at 0°C to room temperature. After completion of the reaction as indicated by TLC, the reaction mixture was quenched with water and extracted with EtOAc (3 × 15 mL). The organic layer was dried

over anhydrous Na_2SO_4 , filtered, concentrated and purified by column chromatography on silica gel using petroleum ether/EtOAc to afford the pure product.

2.2d1 *1-Butyl-3-iodo-1H-indole-2-carboxylic acid methyl ester (4c)*: 74% yield; Brown oil; IR (neat): 2955, 1710, 1463, 1351, 1245, 1199, 1115, 740 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.93 (t, 3H, $J = 7.6$ Hz); 1.33–1.37 (m, 2H); 1.73–1.76 (m, 2H); 3.98 (s, 3H); 4.53 (t, 2H, $J = 7.6$ Hz); 7.22 (t, 1H, $J = 6.9$ Hz); 7.33–7.37 (m, 2H); 7.56 (d, 1H, $J = 7.6$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 13.9, 20.2, 32.8, 45.9, 51.7, 110.7, 121.5, 124.1, 126.1, 128.2, 130.3, 138.5, 161.8. GC-MS: $m/z = 357$ [M^+]. Anal. Calcd for $\text{C}_{14}\text{H}_{16}\text{INO}_2$: C, 47.08; H, 4.52; N, 3.92%. Found: C, 47.21; H, 4.49; N, 3.85%.

2.2d2 *3-Iodo-5-methoxy-1-butyl-1H-indole-2-carboxylic acid methyl ester (4f)*: 72% yield; Colourless solid; M.p. 96–98°C; IR (KBr): 2952, 1706, 1500, 1254, 1204 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.92 (t, 3H, $J = 7.6$ Hz); 1.29–1.36 (m, 2H); 1.69–1.75 (m, 2H); 3.89 (s, 3H); 3.96 (s, 3H); 4.50 (t, 2H, $J = 6.9$ Hz); 6.92 (d, 1H, $J = 2.2$ Hz); 7.03 (dd, 1H, $J_1 = 2.3$ Hz, $J_2 = 9.1$ Hz); 7.24 (d, 1H, $J = 9.1$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 13.9, 20.2, 33.0, 46.0, 51.6, 55.8, 103.6, 111.9, 118.0, 128.1, 130.6, 133.8, 155.5, 161.7. GC-MS: $m/z = 387$ [M^+]. Anal. Calcd for $\text{C}_{15}\text{H}_{18}\text{INO}_3$: C, 46.53; H, 4.69; N, 3.62%. Found: C, 46.81; H, 4.65; N, 3.55%.

2.2d3 *Methyl-1-benzyl-3-iodo-5-methoxy-1H-indole-2-carboxylate (4g)*: 78% yield; Colourless solid; M.p. 98–100°C; IR (KBr): 2938, 2360, 1706, 1500, 1255, 1206 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 3.89 (s, 3H); 3.90 (s, 3H); 5.78 (s, 2H); 6.96 (d, 1H, $J = 2.3$ Hz); 6.99–7.02 (m, 3H); 7.20–7.26 (m, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 49.3, 51.7, 55.8, 103.7, 112.2, 118.4, 126.1, 127.4, 128.4, 128.7, 128.9, 130.9, 134.2, 137.9, 155.8, 161.6. GC-MS: $m/z = 421$ [M^+]. Anal. Calcd for $\text{C}_{18}\text{H}_{16}\text{INO}_3$: C, 51.32; H, 3.83; N, 3.33%. Found: C, 51.50; H, 3.79; N, 3.25%.

2.2e *General procedure for the synthesis of 3-ethynyl-indole-2-carboxylic acid methyl ester 5a–j*: To a mixture of 3-iodo-indole-2-carboxylic acid methyl ester (1.0 mmol), $\text{Pd}(\text{Ph}_3\text{P})_2\text{Cl}_2$ (5.0 mol%) and CuI (5.0 mol%) under N_2 atmosphere was added triethylamine (5 mL) and stirred for 15 min. To this reaction mixture was added the appropriate terminal alkyne (1.1 mmol) and stirred at room temperature for 6 h. After completion of the reaction as indicated by TLC, the reaction mixture was quenched with water (50 mL)

and extracted with EtOAc (3 × 15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated and purified by column chromatography on silica gel using petroleum ether/EtOAc to afford the pure product.

2.2e1 1-Methyl-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5a): 88% yield; Brown paste; IR (neat): 2379, 1707, 1472, 1268, 1119, 745 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 4.02 (s, 3H); 4.03 (s, 3H); 7.27 (t, 1H, *J* = 7.6 Hz); 7.32–7.41 (m, 5H); 7.64 (d, 2H, *J* = 7.6 Hz); 7.91 (d, 1H, *J* = 8.4 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 32.3, 51.9, 83.2, 95.7, 105.0, 110.5, 121.4, 121.7, 124.2, 126.0, 127.9, 128.1, 128.5, 128.9, 131.6, 138.4, 162.1. MS (EI): *m/z* = 289 [M⁺]. Anal. Calcd for C₁₉H₁₅NO₂: C, 78.87; H, 5.23; N, 4.84%. Found: C, 79.10; H, 5.15; N, 4.76%.

2.2e2 1-Ethyl-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5b): 86% yield; Brown oil; IR (neat): 2976, 1701, 1469, 1247, 1124 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.52 (t, 3H, *J* = 6.8 Hz); 4.05 (s, 3H); 4.51 (q, 2H, *J* = 6.9 Hz); 7.27–7.31 (m, 1H); 7.36 (d, 1H, *J* = 7.6 Hz); 7.39–7.44 (m, 4H); 7.65 (d, 2H, *J* = 7.6 Hz); 7.95 (d, 1H, *J* = 8.4 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 15.7, 40.3, 51.9, 83.3, 95.5, 110.5, 121.4, 121.9, 124.3, 126.0, 126.1, 128.0, 128.1, 128.5, 131.5, 131.6, 137.5, 161.5. MS (EI): *m/z* = 303 [M⁺]. Anal. Calcd for C₂₀H₁₇NO₂: C, 79.19; H, 5.65; N, 4.62%. Found: C, 79.31; H, 5.62; N, 4.57%.

2.2e3 1-Butyl-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5c): 79% yield; Yellow liquid; IR (neat): 2926, 1708, 1463, 1359, 1244, 1200, 1124, 745 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.93 (t, 3H, *J* = 6.9 Hz); 1.33–1.40 (m, 2H); 1.75–1.79 (m, 2H); 4.02 (s, 3H); 4.55 (t, 2H, *J* = 7.6 Hz); 7.28–7.33 (m, 1H); 7.38 (d, 1H, *J* = 7.6 Hz); 7.41–7.50 (m, 4H); 7.69 (d, 2H, *J* = 7.6 Hz); 8.00 (d, 1H, *J* = 8.4 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 13.6, 20.1, 32.6, 45.6, 52.0, 83.7, 95.6, 110.7, 121.6, 124.5, 126.1, 126.3, 127.9, 128.2, 128.6, 131.6, 131.8, 137.7, 161.7. MS (EI): *m/z* = 331 [M⁺]. Anal. Calcd for C₂₂H₂₁NO₂: C, 79.73; H, 6.39; N, 4.23%. Found: C, 79.51; H, 6.44; N, 4.30%.

2.2e4 5-Methoxy-1-methyl-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5d): 90% yield; Orange solid; M.p. 182–184 °C; IR (KBr): 2919, 1692, 1498, 1450, 1190, 878 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 3.91 (s, 3H); 4.00 (s, 3H); 4.04 (s, 3H); 7.06 (dd, 1H, *J*₁ = 2.3 Hz, *J*₂ = 9.1 Hz); 7.33–7.39 (m,

3H); 7.60 (d, 2H, *J* = 6.9 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 32.5, 51.8, 55.8, 83.2, 95.5, 101.5, 104.2, 111.5, 117.7, 124.2, 128.0, 128.4, 129.0, 131.5, 133.9, 155.5, 162.1. MS (EI): *m/z* = 319 [M⁺]. Anal. Calcd for C₂₀H₁₇NO₃: C, 75.22; H, 5.37; N, 4.39%. Found: C, 75.01; H, 5.33; N, 3.33%.

2.2e5 5-Methoxy-1-ethyl-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5e): 84% yield; Brown paste; IR (neat): 2340, 1704, 1438, 1209 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.39 (t, 3H, *J* = 6.9 Hz); 3.90 (s, 3H); 3.91 (s, 3H); 4.01 (s, 3H); 4.59 (q, 2H, *J* = 6.9 Hz); 7.05–7.07 (m, 1H); 7.24 (s, 1H); 7.30–7.39 (m, 4H); 7.58–7.60 (d, 2H, *J* = 8.4 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 15.7, 40.4, 51.8, 55.8, 83.2, 95.4, 101.6, 111.5, 117.7, 124.2, 128.0, 128.2, 128.6, 131.4, 131.5, 132.9, 155.5, 161.9. MS (EI): *m/z* = 333 [M⁺]. Anal. Calcd for C₂₁H₁₉NO₃: C, 75.66; H, 5.74; N, 4.20%. Found: C, 75.51; H, 5.70; N, 4.15%.

2.2e6 5-Methoxy-1-butyl-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5f): 72% yield; Brown paste; IR (neat): 2938, 2360, 1706, 1446, 1203, 745 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.93 (t, 3H, *J* = 7.6 Hz); 1.32–1.37 (m, 2H); 1.74–1.77 (m, 2H); 3.91 (s, 3H); 4.00 (s, 3H); 4.54 (t, 2H, *J* = 7.6 Hz); 7.05 (dd, 1H, *J*₁ = 2.3 Hz, *J*₂ = 9.2 Hz); 7.22 (d, 1H, *J* = 3.05 Hz); 7.29–7.37 (m, 4H); 7.59 (d, 2H, *J* = 6.8 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 13.9, 20.2, 32.8, 45.3, 51.9, 55.8, 83.3, 95.5, 101.5, 104.3, 111.8, 117.7, 124.2, 128.0, 128.4, 128.5, 128.6, 131.5, 133.3, 155.4, 161.9. MS (EI): *m/z* = 361 [M⁺]. Anal. Calcd for C₂₃H₂₃NO₃: C, 76.43; H, 6.41; N, 3.88%. Found: C, 76.61; H, 6.36; N, 3.81%.

2.2e7 5-Methoxy-1-benzyl-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5g): 85% yield; Brown solid; M.p. 100–102 °C; IR (KBr): 2945, 1705, 1450, 1239, 1201, 692 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 3.91 (s, 3H); 3.96 (s, 3H); 5.82 (s, 2H); 7.01–7.04 (m, 2H); 7.19–7.28 (m, 6H); 7.32–7.40 (m, 4H); 7.61 (d, 1H, *J* = 6.8 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 48.6, 51.9, 55.8, 83.1, 95.8, 101.7, 105.1, 112.1, 118.0, 124.1, 126.2, 127.4, 128.1, 128.5, 128.7, 128.9, 129.1, 131.6, 133.7, 137.8, 155.7, 161.7. MS (EI): *m/z* = 395 [M⁺]. Anal. Calcd for C₂₆H₂₁NO₃: C, 78.97; H, 5.35; N, 3.54%. Found: C, 79.11; H, 5.27; N, 3.44%.

2.2e8 Methyl-3-(hex-1-ynyl)-1H-indole-2-carboxylate (5h): 67% yield; Yellow solid; M.p. 98–99 °C; IR (KBr): 3317, 1692, 1450, 1217, 736 cm⁻¹. ¹H NMR

(500 MHz, CDCl₃): δ_{H} 0.99 (t, 3H, $J = 6.9$ Hz); 1.56–1.61 (m, 2H); 1.65–1.70 (m, 2H); 2.58 (t, 2H, $J = 6.9$ Hz); 4.00 (s, 3H); 7.20 (t, 1H, $J = 6.9$ Hz); 7.34 (t, 1H, $J = 8.4$ Hz); 7.38 (d, 1H, $J = 7.6$ Hz); 7.78 (d, 1H, $J = 7.6$ Hz); 9.25 (s, 1H). ¹³C NMR (125 MHz, CDCl₃): δ_{C} 13.8, 19.7, 22.0, 31.0, 52.2, 72.8, 97.5, 105.2, 112.0, 121.2, 121.8, 126.2, 127.4, 129.6, 135.6, 162.2. MS (EI): $m/z = 255$ [M⁺]. Anal. Calcd for C₁₆H₁₇NO₂: C, 75.27; H, 6.71; N, 5.49%. Found: C, 75.51; H, 6.66; N, 5.41%.

2.2e9 *Methyl-3-(2-phenylethynyl)-1H-indole-2-carboxylate (5i)*: 85% yield; Brown solid; M.p. 188–189 °C; IR (KBr): 3298, 1673, 1455, 1252, 740 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_{H} 4.05 (s, 3H); 7.25 (t, 1H, $J = 7.6$ Hz); 7.34–7.40 (m, 4H); 7.43 (d, 1H, $J = 7.6$ Hz); 7.61 (d, 2H, $J = 7.6$ Hz); 7.89 (d, 1H, $J = 7.6$ Hz). ¹³C NMR (125 MHz, CDCl₃): δ_{C} 52.4, 82.1, 96.1, 104.3, 112.1, 121.6, 121.8, 123.8, 126.5, 128.0, 128.3, 128.4, 129.2, 131.7, 135.6, 161.9%. MS (EI): $m/z = 275$ [M⁺]. Anal. Calcd for C₁₈H₁₃NO₂: C, 78.53; H, 4.76; N, 5.09%. Found: C, 78.85; H, 4.72; N, 5.02%.

2.2e10 *5-Methoxy-3-phenylethynyl-1H-indole-2-carboxylic acid methyl ester (5j)*: 87% yield; Brown solid; M.p. 202–203 °C; IR (KBr): 3289, 1687, 1469, 1209, 1020 cm⁻¹. ¹H NMR (500 MHz, CDCl₃+DMSO-*d*₆): δ_{H} 3.79 (s, 3H); 3.90 (s, 3H); 6.89 (d, 1H, $J = 9.1$ Hz); 7.09 (s, 1H); 7.23–7.30 (m, 4H); 7.50 (d, 2H, $J = 6.9$ Hz); 10.85 (s, 1H). ¹³C NMR (125 MHz, CDCl₃+DMSO-*d*₆): δ_{C} 47.2, 50.9, 78.1, 90.6, 96.3, 97.9, 109.0, 112.8, 119.2, 123.2, 123.6, 123.7, 124.6, 126.7, 126.8, 150.4, 157.0. MS (EI): $m/z = 305$ [M⁺]. Anal. Calcd for C₁₉H₁₅NO₃: C, 74.74; H, 4.95; N, 4.59%. Found: C, 74.51; H, 4.91; N, 4.51%.

2.2f *General procedure for the alkaline hydrolysis of 3-ethynyl-indole-2-carboxylic acid methyl ester 6a-j*: To a solution of methanol (3 mL), ethanol (1 mL) and water (2 mL) was added 3-ethynyl-indole-2-carboxylate (500 mg) and stirred at room temperature for 5 min. To this reaction mixture was added NaOH (1.5 equiv) and stirred at 75 °C for 1 h. After completion of the reaction as indicated by TLC, the reaction mixture was concentrated under reduced pressure. The residue was quenched with water (10 mL) and extracted with Et₂O (3 × 15 mL) to remove the organic impurities. The aqueous extract was acidified (pH = 1 to 2) with 10% HCl and extracted with EtOAc (3 × 15 mL). The combined organic extract was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford pure product (**6a–j**), which was used for the next step.

2.2g *General procedure for the synthesis of pyrano[3,4-*b*]indol-1(9H)-ones 7a-j*: To a mixture of 3-ethynyl-indole-2-carboxylic acid (1.0 mmol) in acetonitrile (1 mL) under N₂ atmosphere was added AuCl₃ (5 mol%) and refluxed for the specified time (table 1). After completion of the reaction as indicated by TLC, the reaction mixture was concentrated under reduced pressure and poured into water, and extracted with ethyl acetate (3 × 10 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated, and purified by column chromatography on silica gel using petroleum ether/ethyl acetate to afford the pure product.

2.2g1 *9-Methyl-3-phenylpyrano[3,4-*b*]indol-1(9H)-one (7a)*: 84% yield; Yellow solid; M.p. 168–170 °C; IR (KBr): 1711, 1471, 1222, 1063, 742 cm⁻¹. ¹H NMR (500 MHz, DMSO-*d*₆, variable temperature): δ_{H} 4.02 (s, 3H); 7.22–7.23 (m, 1H); 7.36–7.56 (m, 5H); 7.81–7.85 (m, 3H); 8.02–8.04 (m, 1H). ¹³C NMR (125 MHz, DMSO-*d*₆, variable temperature): δ_{C} 31.6, 98.3, 111.6, 120.9, 121.2, 121.4, 122.3, 124.8, 125.6, 128.3, 129.4, 129.5, 132.6, 141.5, 151.6, 156.1. MS (EI): $m/z = 275$ [M⁺]. Anal. Calcd for C₁₈H₁₃NO₂: C, 78.53; H, 4.76; N, 5.09%. Found: C, 78.69; H, 4.72; N, 5.03%.

2.2g2 *9-Ethyl-3-phenylpyrano[3,4-*b*]indol-1(9H)-one (7b)*: 85% yield; Orange solid; M.p. 70–75 °C; IR (KBr): 1712, 1469, 1220, 1061, 739 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_{H} 1.44 (t, 3H, $J = 7.6$ Hz); 4.66 (q, 2H, $J = 7.6$ Hz); 7.24 (t, 1H, $J = 6.9$ Hz); 7.29 (s, 1H); 7.35 (d, 1H, $J = 6.9$ Hz); 7.41–7.43 (m, 3H); 7.49 (t, 1H, $J = 6.9$ Hz); 7.85–7.89 (m, 3H). ¹³C NMR (125 MHz, CDCl₃): δ_{C} 15.9, 39.6, 97.1, 110.7, 120.4, 120.9, 121.4, 121.7, 124.9, 125.9, 127.9, 128.8, 129.1, 132.6, 140.4, 152.4, 156.5. MS (EI): $m/z = 289$ [M⁺].

Table 1. AuCl₃ catalyzed synthesis of pyrano[3,4-*b*]indol-1(9H)-ones.

Entry	Substrate	Product ^a	Time (min)	Yield (%) ^b
1	6a	7a	20	84
2	6b	7b	20	85
3	6c	7c	30	83
4	6d	7d	05	92
5	6e	7e	05	91
6	6f	7f	15	88
7	6g	7g	15	87
8	6h	7h	20	79
9	6i	7i	45	75
10	6j	7j	40	77

^aAll the Products were characterized by IR, ¹H NMR, ¹³C NMR and MS

^bIsolated yield after column chromatography

Anal. Calcd for C₁₉H₁₅NO₂: C, 78.87; H, 5.23; N, 4.84%. Found: C, 78.00; H, 4.28; N, 5.41%.

2.2g3 *9-Butyl-3-phenylpyrano[3,4-b]indol-1(9H)-one (7c)*: 83% yield; Colourless liquid; IR (neat): 2949, 1714, 1059, 743 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.94 (t, 3H, *J* = 7.6 Hz); 1.36–1.42 (m, 2H); 1.84–1.85 (m, 2H); 4.68 (t, 2H, *J* = 7.6 Hz); 7.27 (t, 1H, *J* = 7.6 Hz); 7.36–7.39 (m, 2H); 7.43–7.53 (m, 4H); 7.89–7.94 (m, 3H). ¹³C NMR (125 MHz, CDCl₃): δ_C 14.2, 22.7, 31.7, 44.6, 97.1, 111.0, 120.9, 121.4, 121.7, 124.9, 125.9, 127.8, 128.8, 129.1, 132.7, 140.9, 152.5, 156.6. MS (EI): *m/z* = 317 [M⁺]. Anal. Calcd for C₂₁H₁₉NO₂: C, 79.47; H, 6.03; N, 4.41%. Found: C, 79.69; H, 6.20; N, 4.35%.

2.2g4 *6-Methoxy-9-methyl-3-phenylpyrano[3,4-b]indol-1(9H)-one (7d)*: 92% yield; Brown solid; M.p. 138–140°C; IR (KBr): 3254, 2550, 1666, 1569, 1365, 1057, 658 cm⁻¹. ¹H NMR (500 MHz, Acetone-*d*₆, variable temperature): δ_H 3.86 (s, 3H); 4.14 (s, 3H); 7.18 (s, 1H); 7.38–7.55 (m, 5H); 7.74 (s, 1H); 7.89–7.91 (m, 2H). ¹³C NMR (125 MHz, Acetone-*d*₆, variable temperature): δ_C 30.7, 55.1, 97.5, 101.7, 110.9, 111.9, 119.2, 121.2, 121.6, 124.4, 124.7, 128.7, 128.8, 128.9, 136.9, 151.3, 155.2. MS (EI): *m/z* = 305 [M⁺]. Anal. Calcd for C₁₉H₁₅NO₃: C, 74.74; H, 4.95; N, 4.59%. Found: C, 74.99; H, 4.90; N, 4.51%.

2.2g5 *9-Ethyl-6-methoxy-3-phenylpyrano[3,4-b]indol-1(9H)-one (7e)*: 91% yield; Brown solid; M.p. 118–120°C; IR (KBr): 3447, 1711, 1460, 1237, 1056, 759 cm⁻¹. ¹H NMR (500 MHz, Acetone-*d*₆): δ_H 1.37 (t, 3H, *J* = 6.9 Hz); 3.86 (s, 3H); 4.70 (q, 2H, *J* = 7.6 Hz); 7.17 (dd, 1H, *J*₁ = 2.3 Hz, *J*₂ = 6.9 Hz); 7.37 (t, 1H, *J* = 7.6 Hz); 7.46 (t, 2H, *J* = 7.6 Hz); 7.56–7.58 (m, 2H); 7.76 (s, 1H); 7.89 (d, 2H, *J* = 6.9 Hz). ¹³C NMR (125 MHz, Acetone-*d*₆): δ_C 15.4, 39.4, 55.1, 97.5, 101.9, 111.9, 119.3, 120.4, 121.9, 124.5, 125.1, 128.8, 128.9, 133.0, 135.8, 151.4, 155.1, 155.6. MS (EI): *m/z* = 319 [M⁺]. Anal. Calcd for C₂₀H₁₇NO₃: C, 75.22; H, 5.37; N, 4.39%. Found: C, 75.39; H, 5.33; N, 4.32%.

2.2g6 *9-Butyl-6-methoxy-3-phenylpyrano[3,4-b]indol-1(9H)-one (7f)*: 88% yield; Yellow liquid; IR (neat): 2928, 1711, 1501, 1239, 1060, 762 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.92 (t, 3H, *J* = 7.6 Hz); 1.34–1.38 (m, 2H); 1.81–1.84 (m, 2H); 3.91 (s, 3H); 4.64 (t, 2H, *J* = 6.8 Hz); 7.17 (dd, 1H, *J*₁ = 11.45; *J*₂ = 2.3 Hz); 7.29 (d, 1H, *J* = 2.3 Hz); 7.33 (s, 1H); 7.36–7.39 (m, 2H); 7.44 (t, 2H, *J* = 7.6 Hz); 7.88 (d, 2H, *J* = 7.6 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 13.9,

20.1, 33.0, 44.7, 55.9, 97.2, 101.6, 112.0, 119.4, 121.1, 121.5, 124.8, 125.1, 128.8, 128.9, 132.7, 136.3, 151.8, 154.8, 156.6. MS (EI): *m/z* = 347 [M⁺]. Anal. Calcd for C₂₂H₂₁NO₃: C, 76.06; H, 6.09; N, 4.03%. Found: C, 75.89; H, 6.14; N, 4.13%.

2.2g7 *9-Benzyl-6-methoxy-3-phenylpyrano[3,4-b]indol-1(9H)-one (7g)*: 87% yield; Yellow solid; M.p. 186–188°C; IR (KBr): 3446, 1694, 1233, 1069, 764, 693 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 3.89 (s, 3H); 5.89 (s, 2H); 7.13 (d, 1H, *J* = 7.6 Hz); 7.21–7.26 (m, 5H); 7.30 (s, 1H); 7.33–7.39 (m, 3H); 7.45 (t, 2H, *J* = 7.6 Hz); 7.89 (d, 2H, *J* = 7.6 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 48.2, 55.9, 97.2, 101.8, 112.5, 119.6, 121.9, 124.9, 125.7, 127.1, 127.6, 128.8, 128.9, 129.1, 132.8, 136.4, 137.5, 152.2, 155.1, 156.8, 163.6. MS (EI): *m/z* = 381 [M⁺]. Anal. Calcd for C₂₅H₁₉NO₃: C, 78.72; H, 5.02; N, 3.67%. Found: C, 78.89; H, 4.98; N, 3.60%.

2.2g8 *3-Butylpyrano[3,4-b]indol-1(9H)-one (7h)*: 79% yield; Colourless solid; M.p. 158–160°C; IR (KBr): 3261, 1688, 1621, 748 cm⁻¹. ¹H NMR (500 MHz, CDCl₃+ DMSO-*d*₆): δ_H 0.86 (t, 3H, *J* = 6.9 Hz); 1.31–1.33 (m, 2H); 1.60–1.63 (m, 2H); 2.54 (t, 2H, *J* = 6.9 Hz); 6.62 (s, 1H); 7.11 (t, 1H, *J* = 7.6 Hz); 7.34 (t, 1H, *J* = 7.6 Hz); 7.50 (d, 1H, *J* = 8.4 Hz); 7.73 (d, 1H, *J* = 8.4 Hz); 11.17 (s, 1H). ¹³C NMR (125 MHz, CDCl₃+ DMSO-*d*₆): δ_C 13.8, 22.1, 29.6, 33.3, 98.5, 113.2, 120.5, 120.6, 121.3, 121.5, 126.0, 127.6, 140.3, 156.7, 158.3. MS (EI): *m/z* = 241 [M⁺]. Anal. Calcd for C₁₅H₁₅NO₂: C, 74.67; H, 6.27; N, 5.81%. Found: C, 74.89; H, 6.24; N, 5.75%.

2.2g9 *3-Phenylpyrano[3,4-b]indol-1(9H)-one (7i)*: 75% yield; Yellow solid; M.p. 171–173°C; IR (KBr): 3401, 2921, 1686, 742 cm⁻¹. ¹H NMR (500 MHz, CDCl₃+ DMSO-*d*₆): δ_H 7.13 (t, 1H, *J* = 6.8 Hz); 7.17–7.19 (m, 1H); 7.27 (d, 1H, *J* = 6.8 Hz); 7.34–7.37 (m, 3H); 7.39 (s, 1H); 7.45–7.50 (m, 1H); 7.79 (d, 1H, *J* = 7.6 Hz); 7.84 (d, 1H, *J* = 7.6 Hz); 11.94 (s, 1H). ¹³C NMR (125 MHz, CDCl₃+ DMSO-*d*₆): δ_C 97.7, 113.4, 120.8, 121.4, 121.9, 124.3, 124.8, 125.6, 127.7, 128.9, 129.0, 132.8, 140.6, 151.9, 157.0. MS (EI): *m/z* = 261 [M⁺]. Anal. Calcd for C₁₇H₁₁NO₂: C, 78.15; H, 4.24; N, 5.36%. Found: C, 78.39; H, 4.19; N, 5.26%.

2.2g10 *6-Methoxy-3-phenylpyrano[3,4-b]indol-1(9H)-one (7j)*: 77% yield; Brown solid; M.p. 232–234°C; IR (KBr): 3223, 1707, 1480, 1219, 1080 cm⁻¹. ¹H NMR (500 MHz, CDCl₃+ DMSO-*d*₆): δ_H 3.78 (s, 3H); 6.98 (d, 1H, *J* = 6.9 Hz); 7.23–7.27 (m, 2H); 7.32–7.38

(m, 4H); 7.77 (d, 2H, $J = 7.6$ Hz); 11.86 (s, 1H). ^{13}C NMR (125 MHz, $\text{CDCl}_3 + \text{DMSO-}d_6$): δ_{C} 55.7, 97.8, 101.4, 114.3, 119.2, 121.7, 122.2, 124.7, 125.0, 128.9 (2 carbon), 132.9, 135.9, 151.3, 154.7, 156.9. MS (EI): $m/z = 291$ [M^+]. Anal. Calcd for $\text{C}_{18}\text{H}_{13}\text{NO}_3$: C, 74.22; H, 4.50; N, 4.81%. Found: C, 74.49; H, 4.44; N, 4.73%.

2.2h Experimental procedure for the synthesis of 2-bromo-indole-3-carbaldehyde 9a: To a solution of anhydrous DMF (27.5 g) in anhydrous 1,2-dichloroethane (100 mL) was added POBr_3 (26.8 g, 0.0937 mol) dropwise at 0°C under argon atmosphere. The resulting mixture was allowed to stir for 30 min followed by addition with a solution of 2-oxindole (5.0 g, 0.0375 mol) in dichloroethane (100 mL). The resulting mixture was stirred at room temperature for 24 h and quenched with ice-cold solution of excess $\text{NaOAc}\cdot 3\text{H}_2\text{O}$. The product was extracted with dichloroethane (3×100 mL), dried over anhydrous sodium sulphate and evaporated under reduced pressure. The crude product was further purified by recrystallization using 95% EtOH to afford 5.9 g (82% yield) of analytically pure compound **9a** as a beige solid; M.p. 220 to 222°C . ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ_{H} 7.00–7.05 (m, 2 H), 7.21 (d, 1H, $J = 7.6$ Hz), 8.02 (d, 1H, $J = 7.6$ Hz), 9.80 (s, 1H), 12.21 (s, 1H).

2.2i Experimental procedure for the oxidative esterification of 9a to 10a: To a solution of 2-bromo-indole-3-carbaldehyde (5.0 g, 0.0223 mol) in dry MeOH (100 mL) was added oxone® (3.56 g, 0.0234 mol) portion wise and stirred at room temperature. After 3 h, the reaction mixture was quenched with water (100 mL) and extracted with dichloromethane (3×100 mL). The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford the ester which was used for the next step without further purification.

2.2j General procedure for the N-alkylation of 2-bromo-indole-3-carboxylic acid methyl ester 11a and 11b: To a mixture of NaH (2.0 equiv) in DMF (3 mL) kept at 0°C at N_2 atmosphere was added a solution of 2-bromo-indole-3-carboxylic acid methyl ester **10a** (1.0 equiv) in DMF (2 mL) and stirred for 15 min. To this mixture was added the corresponding alkyl halide (1.2 equiv) and stirred for 3 h at 0°C to room temperature. After completion of the reaction as indicated by TLC, the reaction mixture was quenched with water and extracted with EtOAc (3×10 mL). The organic

layer was dried over anhydrous Na_2SO_4 , filtered, concentrated and purified by column chromatography on silica gel using petroleum ether/EtOAc to afford the pure product.

2.2j1 Methyl 2-bromo-1-methyl-1H-indole-3-carboxylate (11a): 92% yield; colourless liquid; IR (neat): 2919, 2355, 1709, 1457, 1245, 1108, 751 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 3.75 (s, 3H); 4.01 (s, 3H); 7.42 (d, 1H, $J = 7.6$ Hz); 7.55 (t, 1H, $J = 8.4$ Hz); 7.67 (t, 1H, $J = 8.4$ Hz); 8.21 (d, 1H, $J = 7.6$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 33.4, 51.9, 109.9, 110.3, 111.1, 120.5, 121.8, 122.2, 128.9, 138.8, 164.1. MS (EI): $m/z = 267$ [M^+], 269 [M^{+2}]

2.2j2 Methyl 2-bromo-1-ethyl-1H-indole-3-carboxylate (11b): 89% yield; colourless solid; M.p. $73\text{--}75^\circ\text{C}$; IR (KBr): 2925, 1705, 1459, 1218, 1009, 741 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 1.42 (t, 3H, $J = 7.6$ Hz); 3.95 (s, 3H); 4.32 (q, 2H, $J = 7.6$ Hz); 7.45 (d, 1H, $J = 7.6$ Hz); 7.95 (t, 1H, $J = 8.4$ Hz); 8.03 (t, 1H, $J = 8.4$ Hz); 8.44 (d, 1H, $J = 7.66$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 14.6, 43.0, 52.6, 110.6, 111.2, 112.1, 120.0, 122.8, 123.1, 132.1, 138.6, 166.7. MS(EI): $m/z = 281$ [M^+], 283 [M^{+2}]

2.2k General procedure for the N-alkylation of 3-iodo-indole-2-carboxylic acid methyl ester 11c and 11d: To a mixture of KOH (3.0 equiv) in DMSO (3 mL) kept at 0°C was added, 2-bromo-indole-2-carboxylic acid methyl ester **10a** (1.0 equiv) and stirred for 30 min. To this mixture was added the corresponding alkyl halide (5.0 equiv) and stirred for 6 h at 0°C to room temperature. After completion of the reaction as indicated by TLC, the reaction mixture was quenched with water and extracted with EtOAc (3×15 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, concentrated and purified by column chromatography on silica gel using petroleum ether/EtOAc to afford the pure product.

2.2k1 Methyl 2-bromo-1-butyl-1H-indole-3-carboxylate (11c): 75% yield; Colourless solid; M.p. $113\text{--}115^\circ\text{C}$; IR (KBr): 2959, 1715, 1460, 1358, 1256, 1202, 1144, 746 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.88 (t, 3H, $J = 7.6$ Hz); 1.29–1.35 (m, 2H); 1.65–1.71 (m, 2H); 3.97 (s, 3H); 4.21 (t, 2H); 7.34 (d, 1H, $J = 8.1$ Hz); 7.75 (t, 1H, $J = 8.4$ Hz); 8.01 (t, 1H, $J = 8.4$ Hz); 8.38 (d, 1H, $J = 8.1$ Hz). ^{13}C NMR (125 MHz, CDCl_3): δ_{C} 13.5, 20.3, 33.3, 52.8, 53.7, 110.1, 110.9, 111.2, 119.7, 121.9, 122.6, 129.6, 138.6, 166.3. MS(EI): $m/z = 309$ [M^+], 311 [M^{+2}]

2.2k2 *Methyl 1-benzyl-2-bromo-1H-indole-3-carboxylate (11d)*: 80% yield; Colourless solid; M.p. 153–155°C; IR (KBr): 2949, 1716, 1455, 1255, 1209, 767 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 3.88 (s, 3H); 5.67 (s, 2H); 7.27–7.34 (m, 2H); 7.39–7.42 (m, 2H); 7.77 (d, 1H, *J* = 8.2 Hz); 7.86–7.94 (m, 2H); 8.19 (d, 1H, *J* = 8.2 Hz). ¹³C NMR (125 MHz, CDCl₃): δ_C 51.3, 55.9, 110.1, 110.9, 111.4, 120.1, 121.8, 122.9, 126.2, 127.2, 129.0, 134.3, 137.9, 138.2, 166.8. MS(EI): *m/z* = 343 [M⁺], 345 [M⁺²]

2.2l *General procedure for the synthesis of 2-ethynyl-indole-3-carboxylic acid methyl ester 12a-j*: To a mixture of 2-bromo-indole-3-carboxylic acid methyl ester (1.0 mmol), Pd(Ph₃P)₄ (5.0 mol%) and CuI (5.0 mol%) under N₂ atmosphere was added triethylamine (5 mL) and stirred for 30 min. To this reaction mixture was added the appropriate terminal alkyne (1.1 mmol) and stirred at room temperature for 10 h. After completion of the reaction as indicated by TLC, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 × 15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated and purified by column chromatography on silica gel using petroleum ether/EtOAc to afford the pure product.

2.2l1 *Methyl 1-methyl-2-(phenylethynyl)-1H-indole-3-carboxylate (12a)*: 85% yield; Yellow solid; M.p. 89–91°C; IR (KBr): 3381, 2382, 1711, 1475, 1265, 1101, 752 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 3.87 (s, 3H); 4.01 (s, 3H); 7.36–7.59 (m, 6H); 7.67 (t, 1H, *J* = 7.6 Hz); 7.82 (t, 1H, *J* = 7.6 Hz); 8.14 (d, 1H, *J* = 8.1 Hz). ¹³C NMR (500 MHz, CDCl₃): δ_C 37.0, 52.1, 88.1, 90.2, 110.1, 111.9, 122.4, 122.9, 124.1, 125.3, 126.6, 126.8, 129.5, 130.3, 132.1, 136.8, 165.5. MS(EI): *m/z* = 289 [M⁺]

2.2l2 *Methyl 1-ethyl-2-(phenylethynyl)-1H-indole-3-carboxylate (12b)*: 87% yield; Yellow solid; M.p. 103–105°C; IR (KBr): 3398, 2975, 1709, 1467, 1250, 1126, 745 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.27 (t, 3H, *J* = 7.7 Hz); 3.92 (s, 3H); 4.19 (q, 2H, *J* = 7.7 Hz); 7.38–7.48 (m, 4H); 7.59 (d, 2H, *J* = 6.9 Hz); 7.71 (t, 1H, *J* = 7.2 Hz); 7.86 (t, 1H, *J* = 7.2 Hz); 8.04 (d, 1H, *J* = 7.6 Hz). ¹³C NMR (500 MHz, CDCl₃): δ_C 14.3, 42.5, 51.6, 86.8, 90.4, 109.7, 110.4, 110.9, 119.7, 121.8, 122.4, 126.9, 137.1, 165.7. MS(EI): *m/z* = 303 [M⁺]

2.2l3 *Methyl 1-butyl-2-(phenylethynyl)-1H-indole-3-carboxylate (12c)*: 81% yield; Pale yellow solid; M.p. 114–116°C; IR (KBr): 3367, 2925, 1710, 1465, 1365, 1240, 1210, 1129, 763 cm⁻¹. ¹H NMR (500 MHz,

CDCl₃): δ_H 0.91 (t, 3H, *J* = 7.6 Hz); 1.32–1.37 (m, 2H); 1.69–1.75 (m, 2H); 3.95 (s, 3H); 4.19 (t, 2H, *J* = 6.8 Hz); 7.35–7.45 (m, 4H); 7.55 (d, 2H, *J* = 6.9 Hz); 7.77 (t, 1H, *J* = 7.8 Hz); 7.92 (t, 1H, *J* = 7.8 Hz); 8.03 (d, 1H, *J* = 7.1 Hz). ¹³C NMR (500 MHz, CDCl₃): δ_C 13.5, 20.4, 32.4, 52.1, 52.3, 86.6, 90.1, 109.4, 110.5, 111.2, 119.5, 121.3, 121.9, 122.4, 127.1, 128.3, 128.5, 133.3, 138.1, 165.4. MS(EI): *m/z* = 331 [M⁺]

2.2l4 *Methyl 1-benzyl-2-(phenylethynyl)-1H-indole-3-carboxylate (12d)*: 91% yield; Yellow solid; M.p. 168–170°C; IR (KBr): 3356, 2948, 1701, 1245, 1211, 713 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 3.99 (s, 3H); 5.71 (s, 2H); 7.21–7.34 (m, 5H); 7.43–7.51 (m, 3H); 7.58–7.73 (m, 5H); 7.98 (d, 1H, *J* = 6.9 Hz). ¹³C NMR (500 MHz, CDCl₃): δ_C 51.9, 56.0, 87.2, 90.1, 109.5, 110.1, 110.4, 120.0, 121.4, 122.1, 122.5, 125.5, 126.5, 127.4, 128.3, 128.5, 128.7, 132.6, 136.9, 137.2, 166.6. MS(EI): *m/z* = 365 [M⁺]

2.2l5 *Methyl 2-(hex-1-yn-1-yl)-1-methyl-1H-indole-3-carboxylate (12e)*: 74% yield; Colourless solid; M.p. 103–105°C; IR (KBr): 3315, 1695, 1455, 1211, 746 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.88 (t, 3H, *J* = 7.6 Hz); 1.31–1.35 (m, 2H); 1.41–1.44 (m, 2H); 3.72 (s, 3H); 4.08 (s, 3H); 7.28 (d, 1H, *J* = 8.4 Hz); 7.57 (t, 1H, *J* = 7.2 Hz); 7.71 (t, 1H, *J* = 8.4 Hz); 7.89 (d, 1H, *J* = 7.1 Hz). ¹³C NMR (500 MHz, CDCl₃): δ_C 13.0, 21.4, 22.1, 30.5, 36.3, 51.4, 76.5, 77.2, 109.8, 110.7, 112.3, 119.5, 120.4, 122.1, 127.9, 136.7, 167.1. MS(EI): *m/z* = 269 [M⁺]

2.2l6 *Methyl 1-ethyl-2-(hex-1-yn-1-yl)-1H-indole-3-carboxylate (12f)*: 77% yield; Colourless solid; M.p. 109–111°C; IR (KBr): 3325, 1702, 1457, 1218, 739 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.91 (t, 3H, *J* = 7.1 Hz); 1.31 (t, 3H, *J* = 7.6 Hz); 1.37–1.41 (m, 2H); 1.44–1.47 (m, 2H); 2.42 (t, 2H, *J* = 6.9 Hz); 4.01 (s, 3H); 4.25 (q, 2H, *J* = 7.6 Hz); 7.34 (d, 1H, *J* = 8.1 Hz); 7.78–7.85 (m, 2H); 7.91 (d, 1H, *J* = 8.2 Hz). ¹³C NMR (500 MHz, CDCl₃): δ_C 13.3, 14.3, 21.4, 21.9, 30.5, 42.1, 51.8, 76.8, 77.6, 109.8, 110.2, 111.1, 119.5, 121.5, 122.6, 127.6, 138.0, 166.1. MS(EI): *m/z* = 283 [M⁺]

2.2l7 *Methyl 1-benzyl-2-(hex-1-yn-1-yl)-1H-indole-3-carboxylate (12g)*: 72% yield; Pale yellow solid; M.p. 134–136°C; IR (KBr): 3346, 1699, 1461, 1213, 749 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.90 (t, 3H, *J* = 7.6 Hz); 1.35–1.44 (m, 4H); 2.55 (t, 2H, *J* = 6.9 Hz); 4.05 (s, 3H); 7.22–7.35 (m, 5H); 7.53–7.78 (m, 3H); 7.91 (d, 1H, *J* = 7.6 Hz). ¹³C NMR (500 MHz, CDCl₃): δ_C 13.1, 21.3, 21.9, 31.0, 52.3, 56.2, 76.5,

77.4, 109.6, 110.2, 111.3, 119.4, 120.1, 122.4, 125.5, 126.6, 127.8, 128.0, 135.4, 136.8, 165.4. MS(EI): $m/z = 345 [M^+]$

2.218 *Methyl 1-benzyl-2-(hept-1-yn-1-yl)-1H-indole-3-carboxylate (12h)*: 67% yield; Yellow solid; M.p. 151–153°C; IR (KBr): 3317, 1703, 1455, 1218, 749 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.89 (t, 3H, $J = 7.6$ Hz); 1.27–1.51 (m, 6H); 2.49 (t, 2H, $J = 6.9$ Hz); 3.88 (s, 3H); 5.55 (s, 2H); 7.26–7.758 (m, 6H); 7.69–7.74 (m, 2H); 7.95 (d, 1H, $J = 8.1$ Hz). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 14.3, 21.5, 28.3, 30.5, 30.8, 51.9, 55.5, 78.7, 79.9, 109.5, 111.1, 111.7, 120.1, 121.2, 122.4, 125.4, 126.3, 126.9, 127.5, 135.3, 137.3, 167.5. MS(EI): $m/z = 359 [M^+]$

2.219 *Methyl 1-benzyl-2-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-indole-3-carboxylate (12i)*: 65% yield; Colourless paste; IR (CH_2Cl_2): 3489, 3401, 1702, 1449, 1219, 768 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 1.55 (s, 6H); 2.64 (brs, 1H); 3.77 (s, 3H); 5.46 (s, 2H); 7.19–7.37 (m, 6H); 7.49–7.65 (m, 2H); 7.77–7.84 (m, 1H). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 33.1, 50.9, 55.8, 77.7, 80.8, 110.9, 111.9, 112.8, 120.3, 121.5, 122.3, 125.4, 126.5, 128.4, 128.7, 136.8, 138.4, 166.0. MS(EI): $m/z = 348 [M^+ + 1]$

2.2110 *Methyl 1-benzyl-2-(5-hydroxypent-1-yn-1-yl)-1H-indole-3-carboxylate (12j)*: 60% yield; Colourless paste; IR (CH_2Cl_2): 3456, 3389, 1688, 1458, 1212, 745 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 1.63–1.68 (m, 2H); 2.52 (brs, 1H); 2.55 (t, 2H, $J = 6.9$ Hz); 3.55–3.63 (m, 2H); 3.93 (s, 3H); 5.45 (s, 2H); 7.28–7.53 (m, 6H); 7.62–7.68 (m, 2H); 7.72–7.76 (m, 1H). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 14.8, 31.5, 52.4, 54.9, 62.1, 79.9, 86.7, 109.2, 109.8, 110.8, 119.1, 120.3, 121.7, 125.7, 126.5, 127.2, 128.5, 138.5, 139.1, 161.1. MS(EI): $m/z = 348 [M^+ + 1]$

2.2m *General procedure for the alkaline hydrolysis of 2-ethynyl-indole-3-carboxylic acid methyl ester 13a-j*: To a solution of methanol (3 mL), ethanol (1 mL) and water (2 mL) was added 2-ethynyl-indole-3-carboxylate (500 mg) and stirred at room temperature for 5 min. To this reaction mixture was added NaOH (1.5 equiv) and stirred at 75°C for 1 h. After completion of the reaction as indicated by TLC, the reaction mixture was concentrated under reduced pressure. The residue was quenched with water (10 mL) and extracted with Et_2O (3×15 mL) to remove the organic impurities. The aqueous extract was acidified (pH = 1 to 2) with 10% HCl and extracted with EtOAc (3×15 mL). The combined organic extract was dried over anhydrous Na_2SO_4

and concentrated under reduced pressure to afford pure product (**13a-j**), which is used for the next step without purification.

2.2n *General procedure for the synthesis of pyrano[4,3-b]indol-1(5H)-ones 14a-j*: To a mixture of 2-ethynyl-indole-3-carboxylic acid **13a-j** (1.0 mmol) in acetonitrile (1 mL) under N_2 atmosphere was added AuCl_3 (5 mol%) and refluxed for the specified time (table 2). After completion of the reaction as indicated by TLC, the reaction mixture was concentrated under reduced pressure and poured into water, and extracted with ethyl acetate (3×10 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, concentrated, and purified by column chromatography on silica gel using petroleum ether/ethyl acetate to afford the pure product.

2.2n1 *5-Methyl-3-phenylpyrano[4,3-b]indol-1(5H)-one (14a)*: 80% yield; Colourless solid; M.p. 77–79°C; IR (KBr): 3398, 1708, 1476, 11198, 1166, 758 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 4.00 (s, 3H); 6.38 (s, 1H); 7.30–7.45 (m, 5H); 7.62–7.76 (m, 3H); 8.01 (d, 1H, $J = 6.9$ Hz). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 33.9, 98.3, 108.5, 109.9, 120.0, 121.9, 122.1, 125.0, 125.8, 127.4, 127.7, 128.1, 130.4, 136.7, 160.1, 165.4. MS(EI): $m/z = 275 [M-H]^-$; Anal. Calcd for $\text{C}_{18}\text{H}_{13}\text{NO}_2$: C, 78.53; H, 4.76; N, 5.09%. Found: C, 79.0149; H, 4.69; N, 4.98%.

2.2n2 *5-Ethyl-3-phenylpyrano[4,3-b]indol-1(5H)-one (14b)*: 78% yield; Colourless solid; M.p. 83–85°C; IR (KBr): 3388, 1715, 1475, 1230, 1055, 775 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 1.28 (t, 3H, $J = 7.6$ Hz); 4.58 (q, 2H, $J = 7.6$ Hz); 6.40 (s, 1H);

Table 2. AuCl_3 catalyzed synthesis of pyrano[4,3-b]indol-1(5H)-ones.

Entry	Substrate	Product ^a	Time (min)	Yield (%) ^b
1	13a	14a	50	80
2	13b	14b	60	78
3	13c	14c	90	75
4	13d	14d	40	81
5	13e	14e	90	74
6	13f	14f	90	73
7	13g	14g	90	67
8	13h	14h	90	65
9	13i	14i	90	47
10	13j	14j	90	42

^aAll the Products were characterized by IR, ^1H NMR, ^{13}C NMR and MS

^bIsolated yield after column chromatography

7.33–7.49 (m, 5H); 7.60–7.77 (m, 3H); 7.98 (d, 1H, $J = 8.4$ Hz). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 15.5, 45.3, 98.1, 108.3, 109.7, 120.2, 121.1, 122.0, 124.6, 125.5, 127.1, 127.6, 128.4, 130.0, 136.4, 160.3, 165.2. MS(EI): $m/z = 289$ [$\text{M}+\text{NH}_4$] $^+$; Anal. Calcd for $\text{C}_{19}\text{H}_{15}\text{NO}_2$: C, 78.87; H, 5.23; N, 4.84%. Found: C, 79.21; H, 5.16; N, 4.75%.

2.2n3 *5-Butyl-3-phenylpyrano[4,3-*b*]indol-1(5H)-one (14c)*: 75% yield; Colourless solid; M.p. 100–102°C; IR (KBr): 3401, 2952, 1721, 1065, 753 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.91 (t, 3H, $J = 7.6$ Hz); 1.42–1.78 (m, 4H); 4.18 (t, 2H, $J = 6.9$ Hz); 6.31 (s, 1H); 7.32–7.49 (m, 5H); 7.61–7.81 (m, 3H); 8.02 (d, 1H, $J = 7.6$ Hz). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 13.2, 20.6, 33.9, 54.7, 97.9, 108.9, 109.9, 120.8, 121.8, 122.5, 124.3, 125.8, 127.7, 127.9, 128.8, 130.7, 136.7, 160.9, 165.9. MS(EI): $m/z = 316$ [$\text{M}-\text{H}$] $^-$; Anal. Calcd for $\text{C}_{21}\text{H}_{19}\text{NO}_2$: C, 79.47; H, 6.03; N, 4.41%. Found: C, 78.99; H, 6.11; N, 4.55%.

2.2n4 *5-Benzyl-3-phenylpyrano[4,3-*b*]indol-1(5H)-one (14d)*: 81% yield; Pale yellow solid; M.p. 210–212°C; ν_{max} (KBr)/ cm^{-1} 3364, 2960, 2921, 2850, 2358, 2345, 2079, 1715, 1455, 1260, 799; ^1H NMR (500 MHz, CDCl_3): δ_{H} 5.51 (s, 2H); 6.94 (s, 1H); 7.11–7.17 (m, 2H); 7.30–7.40 (m, 6H); 7.42–7.50 (m, 3H); 7.85–7.95 (m, 2H); 8.25–8.35 (m, 1H); ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 47.7, 91.4, 100.9, 110.3, 121.9, 123.3, 124.8, 125.3, 126.1, 126.6, 128.6, 129.3, 129.6, 130.8, 132.6, 135.9, 139.2, 146.7, 159.1, 159.6; MS(EI): $m/z = 352$ [$\text{M}+\text{H}$] $^+$; Anal. Calcd for $\text{C}_{24}\text{H}_{17}\text{NO}_2$: C, 82.03; H, 4.88; N, 3.99%. Found: C, 81.79; H, 4.95; N, 4.09%.

2.2n5 *3-Butyl-5-methylpyrano[4,3-*b*]indol-1(5H)-one (14e)*: 74% yield; Colourless solid; M.p. 87–89°C; IR (KBr): 3055, 3012, 1701, 1622, 1611, 812 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.91 (t, 3H, $J = 7.6$ Hz); 1.27–1.44 (m, 4H); 4.04 (s, 3H); 5.87 (s, 1H); 7.62 (d, 1H, $J = 8.1$ Hz); 7.69–7.75 (m, 2H); 7.96 (d, 1H, $J = 8.1$ Hz). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 14.1, 22.5, 25.9, 33.2, 33.9, 99.9, 109.8, 110.2, 119.2, 122.3, 123.2, 127.8, 138.9, 161.4, 167.8. MS(EI): $m/z = 255$ [M^+]. Anal. Calcd for $\text{C}_{16}\text{H}_{17}\text{NO}_2$: C, 75.27; H, 6.71; N, 5.49%. Found: C, 74.89; H, 6.79; N, 5.61%.

2.2n6 *3-Butyl-5-ethylpyrano[4,3-*b*]indol-1(5H)-one (14f)*: 73% yield; Colourless solid; M.p. 94–96°C; IR (KBr): 3148, 2978, 1712, 1625, 1605, 834 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.88 (t, 3H, $J = 6.9$ Hz); 1.28 (t, 3H, $J = 7.6$ Hz); 1.31–1.38 (m, 4H); 1.89 (t,

2H, $J = 7.1$ Hz); 4.49 (q, 2H, $J = 7.6$ Hz); 5.86 (s, 1H); 7.44–7.56 (m, 3H); 7.67–7.74 (m, 1H). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 13.9, 15.2, 22.5, 26.4, 33.6, 43.6, 98.7, 109.2, 110.8, 119.8, 122.9, 123.6, 127.2, 139.4, 161.5, 166.4. MS(EI): $m/z = 269$ [M^+]. Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{NO}_2$: C, 75.81; H, 7.11; N, 5.20%. Found: C, 76.25; H, 7.19; N, 5.32%.

2.2n7 *5-Benzyl-3-butylpyrano[4,3-*b*]indol-1(5H)-one (14g)*: 67% yield; Colourless solid; M.p. 103–105°C; IR (KBr): 3148, 3025, 1705, 1625, 832, 717 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} (0.91 (t, 3H, $J = 7.6$ Hz); 1.29–1.38 (m, 4H); 2.00 (t, 2H, $J = 6.9$ Hz); 5.82 (s, 2H); 5.91 (s, 3H); 7.22–7.48 (m, 7H); 7.77 (d, 1H, $J = 8.1$ Hz); 7.94 (d, 1H, $J = 8.1$ Hz). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 14.2, 22.5, 25.9, 33.3, 51.3, 100.1, 108.5, 110.1, 119.9, 122.4, 125.3, 125.7, 127.7, 129.2, 133.9, 139.9, 161.8, 167.6. MS(EI): $m/z = 330$ [$\text{M}-\text{H}$] $^-$; Anal. Calcd for $\text{C}_{22}\text{H}_{21}\text{NO}_2$: C, 79.73; H, 6.39; N, 4.23%. Found: C, 80.09; H, 6.50; N, 4.37%.

2.2n8 *5-Benzyl-3-pentylpyrano[4,3-*b*]indol-1(5H)-one (14h)*: 65% yield; Colourless solid; M.p. 120–122°C; IR (KBr): 3155, 3035–2865, 1715, 1625, 1610, 848 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 0.89 (t, 3H, $J = 6.6$ Hz); 1.25–1.33 (m, 4H); 1.66–1.80 (m, 2H); 2.55 (t, 2H, $J = 8.1$ Hz); 5.39 (s, 2H); 6.25 (s, 1H); 7.02–7.11 (m, 3H); 7.24–7.33 (m, 6H); 7.00–8.04 (m, 1H). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 14.2, 22.6, 27.0, 31.2, 34.5, 47.6, 92.8, 99.5, 110.0, 121.3, 122.9, 124.5, 126.2, 128.1, 129.2, 135.6, 138.3, 146.6, 160.1, 164.5. MS(EI): $m/z = 346$ [$\text{M}+\text{H}$] $^+$; Anal. Calcd for $\text{C}_{23}\text{H}_{23}\text{NO}_2$: C, 79.97; H, 6.71; N, 4.05%. Found: C, 80.25; H, 6.77; N, 4.16%.

2.2n9 *5-Benzyl-3-(2-hydroxypropan-2-yl)pyrano[4,3-*b*]indol-1(5H)-one (14i)*: 47% yield; Colourless solid; M.p. 155–157°C; IR (KBr): 3589, 3449, 3115–2915, 1700, 1681, 834 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ_{H} 1.65 (s, 6H); 3.02 (brs, 1H); 5.30 (s, 2H); 6.81 (s, 1H); 6.99–7.06 (m, 2H); 7.22–7.37 (m, 6H); 8.19–8.25 (m, 1H). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 28.6, 47.0, 71.9, 89.8, 99.5, 110.0, 121.2, 122.9, 124.1, 124.6, 126.2, 128.0, 129.0, 135.6, 138.3, 146.4, 159.5, 168.5. MS(EI): $m/z = 332$ [$\text{M}-\text{H}$] $^+$; Anal. Calcd for $\text{C}_{21}\text{H}_{19}\text{NO}_3$: C, 75.66; H, 5.74; N, 4.20%. Found: C, 76.01; H, 5.65; N, 4.08%.

2.2n10 *5-Benzyl-3-(3-hydroxypropan-2-yl)pyrano[4,3-*b*]indol-1(5H)-one (14j)*: 42% yield; Orange solid; M.p. 148–150°C; IR (KBr): 3415, 2925, 2859, 1695, 1559, 832, 789 cm^{-1} . ^1H NMR (500 MHz, CDCl_3):

δ_{H} 1.69 (brs, 1H); 1.91–2.05 (m, 2H), 2.75 (t, 2H, $J = 7.6$ Hz), 3.70 (t, 2H, $J = 6.4$ Hz), 5.38 (s, 2H), 6.35 (s, 1H), 7.03–7.12 (m, 2H); 7.22–7.38 (m, 6H); 8.15–8.25 (m, 1H). ^{13}C NMR (500 MHz, CDCl_3): δ_{C} 30.3, 31.1, 47.2, 61.9, 93.0, 99.6, 110.0, 121.5, 122.9, 124.6, 124.5, 126.3, 128.1, 129.3, 135.7, 138.5, 146.7, 160.1, 163.5. MS(EI): $m/z = 351$ [$\text{M} + \text{NH}_4$] $^+$; Anal. Calcd for $\text{C}_{21}\text{H}_{19}\text{NO}_3$: C, 75.66; H, 5.74; N, 4.20%. Found: C, 75.35; H, 5.79; N, 4.28%.

2.3 Experimental procedure for the evaluation of cytotoxicity

The HeLa cells were seeded into 96-well plates in 100 μL of medium containing 5% fetal bovine serum (FBS), at plating density of 10,000 cells/well and incubated at 37°C, 5% CO_2 , 95% air and 100% relative humidity for 24 h prior to addition of samples. The samples were solubilized in DMSO and diluted in serum free medium. After 24 h, 100 μL of the medium containing the samples at various concentrations were added and incubated at 37°C, 5% CO_2 , 95% air and 100% relative humidity for 48 h. Triplicate was maintained and the medium containing without samples were served as control. After 48 h, 15 μL of MTT (5 mg/mL) in Dulbecco's phosphate buffered saline (DPBS) was added to each well and incubated at 37°C for 4 h. The medium with MTT was then flicked off and the formed formazan crystals were solubilized in 100 μL of DMSO and then the absorbance was measured at 570 nm using micro plate reader. The percentage growth of inhibition of was calculated by comparing the results of the test with those of the control using the formula: % inhibition = $(A_{\text{C}} - A_{\text{T}}) / A_{\text{C}} \times 100$, where A_{C} is the absorbance of control and A_{T} is the absorbance of test. From the results nonlinear regression graph was plotted between % cell growth inhibition and Log_{10} concentration (μM). The half maximal inhibitory concentration (IC_{50} value) was determined using GraphPad Prism software.

2.4 Molecular docking


Molecular docking simulation was performed using the AutoDock Tools (ADT) version 1.5.6 and AutoDock version 4.2.5.1 docking program. Three dimensional structure of VHR receptor was obtained from the Protein Data Bank (PDB ID: 3F81). The co-crystallized ligand in the 3F81 structure was removed. Then, the water molecules present with the crystal were deleted, the polar hydrogen atoms were added, lower occupancy residue structures were deleted, and any incomplete

side chains were replaced using the ADT. Gasteiger charges were added to each atom and merged the non-polar hydrogen atoms to the protein structure. The hydrogen bond distance between donor and acceptor atoms was defined as 1.9 Å with a tolerance of 0.5 Å, and the acceptor–hydrogen–donor angle was not less than 120°. Then, the structures were saved in PDBQT file format for further studies in ADT. ChemDraw Ultra 7.0 (ChemOffice 2002) was used to draw the Ligand 2D structures. Then, Chem3D Ultra 7.0 was used to convert 2D structure into 3D, and semi-empirical AM1 method was used to minimize the energy. Minimum RMS gradient of 0.100 was set in each iteration to minimize the energy. All structures were saved as .pdb file format for input to ADT. All the ligand structures were then saved in PDBQT file format, to carry out docking in ADT. A grid box with dimension of $40 \times 40 \times 40 \text{ \AA}^3$ with 0.375 Å spacing centred on $-0.908, 0.681, -6.463$ was created around the binding site of co-crystallized ligand on 3F81 protein using ADT. The centre of the box was set at co-crystallized ligand centre and grid energy calculations were carried out. AutoDock docking calculation was done using default parameters and 50 docked conformations were generated for each compound. Genetic algorithms were used to calculate the energy of the binding interactions. The outputs were exported to PyMOL for visual inspection of the binding modes and interactions of the compounds with amino acid residues in the active sites.

3. Results and Discussion

3.1 Chemistry

3.1a *Chemical synthesis of pyrano[3,4-*b*]indol-1(9*H*)-ones*: The synthetic pathway of pyrano[3,4-*b*]indol-1(9*H*)-ones is outlined in scheme 1. Indole-2-carboxylic acid **1a-b** was esterified with methanol using catalytic sulphuric acid to afford the corresponding methyl ester **2a-b**.⁷ The esters were then subjected to C3-iodination using molecular iodine to afford 3-iodoindole-2-carboxylate **3a-b**.⁸ N-alkyl-3-iodoindole-2-carboxylate **4a-g** was obtained by N-alkylation reaction of **3a-b** using respective alkyl halide and base.⁹ 3-(Ethynyl)-indole-2-carboxylate **5a-j** was obtained by coupling terminal alkynes with 3-iodo indoles **3a-b** and **4a-j** under standard Sonagashira condition.¹⁰ Hydrolysis of **5a-j** was achieved using aqueous sodium hydroxide in an ethanol-methanol solution to give 3-(ethynyl)-indole-2-carboxylic acid **6a-j**.¹¹ Having synthesized the starting materials in satisfactory yields, we then focused our attention on the cyclization of substrates **6a-j**.




Scheme 1. (a) H₂SO₄ (catalytic), MeOH, reflux, 24 h (b) I₂ (1.2 equiv.), KOH (3.0 equiv.), DMF, rt, 6 h (c) (for **4a**, **4b**, **4d** and **4e**) NaH (2.0 equiv), DMF, 30 min at 0°C then R²X (3.0 equiv), 0°C to rt, 6 h (for **4c**, **4f** and **4g**) KOH (3.0 equiv), DMSO, 30 min at 0°C then R²X (5.0 equiv), 0°C to rt, 6 h (d) PdCl₂(Ph₃P)₂ (5 mol%), CuI (5 mol%), alkyne, (1.1 equiv), Et₃N, 6 h, rt (e) NaOH (1.5 equiv), MeOH/EtOH / H₂O (3:1:2), 75°C, 1 h (f) AuCl₃ (5 mol%), MeCN, reflux.

Cycloisomerization of substrates **6a-j** in the presence of 5 mol% of AuCl₃ in refluxing acetonitrile gave the pyranoindolones **7a-j** with good to excellent yields as single regioisomer. The results were shown in table 1, which indicate that the reaction proceeded at a short reaction time in N-alkyl indoles than unsubstituted indoles. Significant increase in yield of the product was observed in N-alkyl indoles **7a-g**, whereas a slight decrease in the product yield was observed in N-unsubstituted indoles **7h-j**. These observations suggest that the presence of electron releasing N-alkyl group enhances the electron density of the triple bond, thus coordinating with the Lewis acidic AuCl₃ with ease. The presence of electron releasing substituent (MeO-) in the aryl ring also enhances the reaction as evidenced by the short reaction time and excellent yield **7d-g**. The structures of all the synthesized compounds were confirmed by spectral data (FTIR, ¹H NMR, ¹³C NMR and EI-MS) and elemental analyses. Pyrano[3,4-*b*]indol-1(9*H*)-one derivatives **7a-j** showed C=O stretching bands in the region of 1666–1714 cm⁻¹ in their IR spectrum, indicating the presence of a δ- lactone ring. In ¹H NMR spectrum, a prominent singlet at δ_H = 6.62–7.76 ppm ascertained

the presence of C4-hydrogen of the indolone ring. In ¹³C NMR spectrum the lactone carbonyl and C4-carbon resonated at δ_C = 155.2–163.6 and 97.1–98.5 ppm respectively. All these findings confirmed the formation of products.

3.1b Chemical synthesis of pyrano[4,3-*b*]indol-1(5*H*)-ones: With an efficient protocol for the synthesis of pyrano[3,4-*b*]indol-1(9*H*)-ones in hand, we next set out to investigate the scope and limitations of our gold catalytic system towards the synthesis of its positional isomer, pyrano[4,3-*b*]indol-1(5*H*)-ones. The required 2-(Ethynyl)-indole-2-carboxylic acids can be easily prepared according to standard literature procedures as shown in scheme 2. Vilsmeier bromoformylation of oxindole **8a** affords 2-bromo-indole-3-carbaldehyde **9a** in excellent yield.¹² Oxidative esterification of **9a** with oxone in methanol gave the ester **10a**.¹³ N-alkylation of **10a** was performed with appropriate alkyl halide and base which results in the formation of N-alkyl derivatives **11a-d**.⁹ By subjecting **11a-d** and terminal acetylenes under standard Sonogashira



Scheme 2. (a) POBr₃ (2.5 equiv.), DMF (10 equiv.), (CH₂)₂Cl₂, 0°C to rt, 24 h (b) Oxone® (1.05 equiv.), MeOH, rt 3 h (c) (for **11a** and **11b**) NaH (2.0 equiv.), DMF, 30 min at 0°C then R²X (3.0 equiv.), 0°C to rt, 6 h (for, **11c** and **11d**) KOH (3.0 equiv.), DMSO, 30 min at 0°C then R²X (5.0 equiv.), 0°C to rt, 6 h (d) Pd(Ph₃P)₄ (5 mol%), CuI (5 mol%), terminal alkyne, (1.1 equiv), Et₃N, 6 h, (e) NaOH (1.5 equiv), MeOH / EtOH / H₂O (3:1:2), 75°C, 1 h (f) AuCl₃ (5 mol%), MeCN, reflux.

cross-coupling reaction yields the acetylenic derivatives **12a-j**.¹⁰ Alkaline hydrolysis of **12a-j** affords the requisite 2-(ethynyl)-indole-3-carboxylic acid **13a-j**.¹¹ In the light of our previous study,^{3d} we subjected the acetylenic precursors **13a-j** with 5 mol% of AuCl₃ under refluxing condition. Gratifyingly, the reaction proceeds and affords the corresponding products **14a-j** in moderate to good chemical yields (table 2). It is noteworthy to mention that precursors **13aj** led to reasonable conversion with only an increase of the reaction time as compared to its positional isomer **6a-j**. This can be attributed to the reduced electrophilicity of carboxylic acid in C3-indole (as in **13a-j**) compared to that of C2-indole (as in **6a-j**). The low yield observed in compounds **14i** and **14j** can be rationalized by the decrease in Lewis acidity of the catalyst by interacting with the hydroxyl function and eventually the catalytic efficiency of the overall process. Similar to our previous results,^{3d} we found that the cycloisomerization follows 6-*endodig* regiochemistry leading to δ -lactone and no γ -lactone was observed as evidenced by crude NMR analysis. This can be ascribed to the energetic inaccessibility or greater strain of 5-5 ring formation over 5-6 ring formation. The formation of δ -lactone ring in all compounds was ascertained by stretching band between 1695 and 1721 cm⁻¹ in their IR spectrum. In ¹H NMR spectrum a singlet between δ_{H} 5.86 and 6.81 ppm were observed, characteristic of the C4-hydrogen of **14a-j**. Moreover all compounds exhibited two characteristic peaks in their ¹³C NMR spectrum at δ_{C} = 97.9–100.1 and 163.5–168.5 ppm, thus confirming the presence of C4-carbon and lactone carbonyl carbon of **14a-j**, respectively.

3.2 Biology

In pursuance of our on-going project on bio-active heterocycles,^{3k-t} an attempt was made to evaluate the cytotoxicity of compounds (**7a-j** and **14a-j**) against human adenocarcinoma cell lines. Towards this end, the MTT [3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyl-tetrazolium bromide] cell proliferation assay was used to evaluate the cytotoxic activity of the synthesized compounds against HeLa cell lines.¹⁴ Results of the *in vitro* anticancer activity were compared with reference drug *cisplatin*. Analysis of the screening data (table 3) revealed that compounds **7d**, **7e** and **7j** showed comparable anticancer potency with IC₅₀ values of 0.22, 1.2 and 0.33 μM , respectively with respect to the reference drug, *cisplatin* (IC₅₀ = 0.08 μM). The results indicated that the presence of methoxy substituent on the C-6 position was found to be essential for activity, since compounds without 6-MeO groups showed a significant loss of potency. A small substituent like methyl on the nitrogen atom **7d** (IC₅₀ = 0.22 μM) exhibited maximum potency compared to other analogues. Replacement of the N-methyl group with an N-ethyl group **7e** (IC₅₀ = 1.20 μM) decreased the potency appreciably, whereas N-butyl group **7f** (IC₅₀ = 5.00 μM) showed even much reduced inhibitory potency. The loss of activity was observed due to the increase on group size from methyl to ethyl to butyl for compounds **7d-f**. However, similar behaviour was not observed in molecules devoid of 6-MeO group such as **7a**, **7b** and **7c** as evidenced by the inconsistent IC₅₀ values (1.90, 11.31 and 3.20 μM , respectively). Although the reason was not clear, it was attributed to the favourable structural

combination of 6-MeO and N-alkyl groups to exhibit better anticancer activity. Interestingly, the absence of alkyl substituent on the indole nitrogen **7j** ($IC_{50} = 0.33 \mu M$) seems to be the second most active among the tested compounds. In contrast, the related compound **7i** ($IC_{50} = 19.1 \mu M$) emerged as the least attractive compound in this series showing poor activity. A moderate cytotoxicity was observed for compound with 3-butyl group **7h** ($IC_{50} = 2.60 \mu M$). Next, we turned our attention in comparing the SAR of the pyrano[4,3-*b*]indol-1(5*H*)-one series **14a-j** (table 3). From the analysis of the observed data, it was found that compound **14d** possessing C3-phenyl and N-benzyl substituent showed highest activity ($IC_{50} = 0.69 \mu M$). Compound **14c** which contains C3-butyl and N-butyl groups emerged as the second most active in the series ($IC_{50} = 1.11 \mu M$). However, replacement of N-butyl by a small group like methyl (**14a**) marginally reduced the inhibitory potency to $1.24 \mu M$. By increasing the chain length to ethyl at the nitrogen atom (**14b**), a slight decrease in activity was observed ($IC_{50} = 1.41 \mu M$). Switching from phenyl to aliphatic chains such as butyl and pentyl as a C3-substituent (**14e-h**) exhibited only moderate potency with the IC_{50} values ranging between 1.63 and $1.92 \mu M$. Compounds possessing tertiary and primary hydroxyl (**14i** and **14j**) emerged as less active among the tested series ($IC_5 = 2.02$ and $2.25 \mu M$, respectively) suggesting the intolerance of polar substituent at the C3-site. These qualitative assessments revealed that the presence of C3-phenyl substituent (as in **14a-d**) is essential for exhibiting good inhibitory potency. An overall comparison of the results suggested that pyrano[4,3-*b*]indol-1(5*H*)-ones **14a-j** exert consistent IC_{50} values (0.69 - $2.89 \mu M$ against the analogous positional isomers **7a-j** (0.22 - $19.11 \mu M$)).

3.3 Molecular docking

In pharmaceutical drug design, the discovery of small molecules that predominantly undergo non-covalent interactions such as hydrogen bonding, van der Waals, π - π and π -cationic interactions in protein-ligand binding is an important concept.¹⁵ This *in silico* approach involves the docking of synthesized compounds into the active site of the 3D structure of the target, followed by the calculation of free energy of binding (FEB) of the protein-ligand complex. The binding mode of the potent inhibitors was investigated using AutoDock Tools (ADT) version 1.5.6 and AutoDock version 4.2.5.1 docking program to rationalize the pharmacological results.¹⁶ To gain insights of the observed activity, we docked all the compounds to Vaccinia H1-Related (VHR) Phosphatase receptor (PDB ID:

Table 3. Anticancer potency of compounds **7a-j** and **14a-j** in HeLa cell lines.

Entry	Compound	$IC_{50}(\mu M)$
1	7a	1.90
2	7b	11.31
3	7c	3.20
4	7d	0.22
5	7e	1.20
6	7f	5.00
7	7g	6.70
8	7h	2.60
9	7i	19.11
10	7j	0.33
11	14a	1.24
12	14b	1.41
13	14c	1.11
14	14d	0.69
15	14e	1.92
16	14f	1.89
17	14g	1.75
18	14h	1.63
19	14i	2.02
20	14j	2.25
21	<i>cis</i> -platin	0.08

3F81) crystal structures available in the Protein Data Bank. A link between VHR and cervical cancer was well established. Compared to normal keratinocytes, VHR protein levels are found to be up regulated in several cervix cancer cell lines including human papilloma virus (CaSki, HeLa, SiHa, HT3 and C33). Biopsies of the primary cervix cancer, squamous intra-epithelial lesions and squamous cell carcinomas of the uterine cervix revealed the higher expression levels of VHR protein level. This clearly suggests that in the treatment of cervical cancer, VHR might be a promising drug target and VHR inhibiting small-molecules could be a potential drug to cure the cervical cancer.¹⁷

To start with, the reproducibility of docking calculations was verified by extracting the co-crystallized ligand from the complexes and submitted for one-ligand run calculation. This reproduced top scoring conformation falling within root-mean-square deviation (RMSD) value of 1.04 \AA with bound X-ray conformation for 3F81, suggesting this method is valid enough to be used for docking studies of other compounds (figure S1 in Supplementary Information). Docking simulation of all the synthesized compounds was performed in the same active site using the same protocol used for the validation study (figure S2 in SI). For each of the test molecules, dockings were performed by taken into 2.5 million energy evaluations. The conformations of docked ligand with VHR receptor were analyzed in terms of energy, hydrogen bonding, hydrophobic and π - π interaction. The final coordinates of the ligand and

receptor were saved after the clear analysis of ligand-receptor interactions. To investigate the interactions of ligand and receptor simulated conformations output was exported to PyMOL software. The free energy of binding (FEB) of all compounds were calculated from the docking scores (table 4).

The results revealed that all the docked compounds bind with the receptor and exhibits free energy of binding value between -5.00 and -8.27 kcal/mol. All the compounds binds in the active site and the simulated conformation exhibits various interactions with 16 amino acids namely LEU-25, PRO-26, PHE-68, MET-69, ASP-92, CYS-124, ARG-125, GLU-126, GLY-127, TYR-128, SER-129, ARG-130, ARG-158, GLY-161, PRO-162 and ASN-163 with non-covalent interactions such as hydrophobic, hydrophilic, π - π interaction and hydrogen bonding. Among all compounds docked, **7d** exhibits very high binding with 3F81 receptor and forms two hydrogen bonds with TYR-128 and SER-129 amino acids which resulted in the binding energy of -6.27 kcal/mol (figure S6 in SI). In compound **7d**, oxygen of O-CH₃ interacts with the hydrogen of NH of TYR-128 and forms a hydrogen bond with the bond length of 2.7 Å. Similarly, oxygen of O-CH₃ interacts with the hydrogen of NH of SER-129 and forms a hydrogen bond with the bond length of 2.2 Å. In addition, benzyl moiety exhibits hydrophobic interaction with GLY-161 and PRO-162 in addition to π - π interaction with the phenyl ring of TYR-128. It is to be

noted that compound **7d** with highest binding energy (-8.27 kcal/mol) did exhibit significant IC₅₀ value ($0.22 \mu\text{M}$), thus establishing a correlation with the biological results.

4. Conclusions

In continuation to our previous work on the synthesis of pyrano[3,4-*b*]indol-1(9*H*)-ones, we further extended our studies towards the synthesis of the corresponding pyrano[4,3-*b*]indol-1(5*H*)-ones. The synthetic potential of gold(III) chloride in the flexible synthesis of isomeric pyranoindolones in excellent regioselectivity and good chemical yields was also demonstrated. All compounds were evaluated for their cytotoxic potency towards HeLa cells and compared with the reference drug *cis*-platin. The results of which indicated that three candidates **7d**, **7j** and **14d** exhibited significant inhibitory potency with IC₅₀ values of 0.22, 0.33 and $0.69 \mu\text{M}$, respectively. Molecular docking with VHR phosphatase receptor also supported the biological results by showing compound **7d** as the most active with a free energy of binding -8.27 kcal/mol. Further investigations to delineate the scope and limitations of the current protocol to biologically active natural products are actively underway in our laboratory and the results will be disclosed in the due course.

Supplementary information (SI)

Copies of molecular docking pictures, ¹H NMR, ¹³C NMR and mass spectra of selected compounds are provided in the Supplementary Information, which is available at www.ias.ac.in/chemsci.

Acknowledgements

C.P. gratefully acknowledges the Science and Engineering Research Board (SERB), India for providing Fast Track award under Young Scientist Scheme (SERB/F/5666/2015-16). C.P. extends his acknowledgement to Dr. Vijayamohan K. Pillai, Director, CSIR-CECRI and Dr. D. Jeyakumar, Head, Functional Materials Division, CSIR-CECRI for providing infrastructure facilities.

References

- (a) Fürstner A 2014 *Acc. Chem. Res.* **47** 925; (b) Hashmi A S K and Rudolph M 2008 *Chem. Soc. Rev.* **37** 1766; (c) Zhang Y, Luo T and Yang Z 2014 *Nat. Prod. Rev.* **31** 489

Table 4. FEB values of compounds on VHR phosphatase receptor.

Entry	Compound	FEB (kcal/mol) ^a
1	7a	-6.39
2	7b	-6.26
3	7c	-6.67
4	7d	-8.27
5	7e	-6.13
6	7f	-6.45
7	7g	-6.43
8	7h	-5.67
9	7i	-6.25
10	7j	-6.07
11	14a	-5.89
12	14b	-5.86
13	14c	-6.10
14	14d	-7.27
15	14e	-5.17
16	14f	-5.00
17	14g	-6.31
18	14h	-6.47
19	14i	-6.77
20	14j	-6.51

^aFree energy of binding (PDB ID: 3F81)

2. (a) Hashmi A S K, Schwarz L, Choi J-H and Frost T M 2000 *Angew. Chem. Int. Ed.* **39** 2285; (b) Hashmi A S K, Frost T M and J W Bats 2000 *J. Am. Chem. Soc.* **122** 11553
3. (a) Praveen C, Karthikeyan K and Perumal P T 2009 *Tetrahedron* **65** 9244; (b) Praveen C, Kalyanasundaram A and Perumal P T 2010 *Synlett* 777; (c) Praveen C and Perumal P T 2011 *Synlett* 521; (d) Praveen C, Ayyanar A and Perumal P T 2011 *Bioorg. Med. Chem. Lett.* **21** 4170; (e) Praveen C and Perumal P T 2016 *Chin. J. Catal.* **37** 288; (f) Jeyaveeran J C, Praveen C, Arun Y, Prince A A M and Perumal P T 2016 *J. Chem. Sci.* **128** 73; (g) Praveen C, Sagayaraj Y W and Perumal P T 2009 *Tetrahedron Lett.* **50** 644; (h) Praveen C, Kiruthiga P and Perumal P T 2009 *Synlett* 1990; (i) Praveen C, Jegatheesan S and Perumal P T 2009 *Synlett* 2795; (j) Praveen C and Perumal P T 2016 *Synthesis* **48** 855; (k) Praveen C, Dheenkumar P, Muralidharan D and Perumal P T 2010 *Bioorg. Med. Chem. Lett.* **20** 7292; (l) Praveen C, Ayyanar A and Perumal P T 2011 *Bioorg. Med. Chem. Lett.* **21** 4072; (m) Praveen C, Iyyappan C, Girija K, Kumar K S and Perumal P T 2012 *J. Chem. Sci.* **124** 451; (n) Praveen C, Nandakumar A, Dheenkumar P, Muralidharan D and Perumal P T 2012 *J. Chem. Sci.* **124** 609; (o) Praveen C, Narendiran S, Dheenkumar P and Perumal P T 2013 *J. Chem. Sci.* **125** 1543; (p) Praveen C, Dheenkumar P and Perumal P T 2013 *J. Chem. Sci.* **125** 71; (q) Parthasarathy K, Praveen C, Balachandran C, Kumar P S, Ignacimuthu S and Perumal P T 2013 *Bioorg. Med. Chem. Lett.* **23** 2708; (r) Parthasarathy K, Praveen C, Kumar P S, Balachandran C and Perumal P T 2015 *RSC Adv.* **5** 15818; (s) Praveen C, Iyyappan C, Perumal P T and Girija K 2012 *Ind. J. Chem.* **51B** 498; (t) Praveen C, Parthasarathy K, Kumar, P S and Perumal P T 2015 *Ind. J. Chem.* **54B** 373
4. Shimizu M, Hirano K, Satoh T and Miura M 2009 *J. Org. Chem.* **74** 3478
5. Suresh R R and Swamy K C K 2012 *J. Org. Chem.* **77** 6959
6. Ngi S I, Guilloteau V, Abarbri M and Thibonnet J 2011 *J. Org. Chem.* **76** 8347
7. Agnusdei M, Bandini M, Melloni A and Umani-Ronchi A 2003 *J. Org. Chem.* **68** 7126
8. (a) Choshi T, Sada T, Fujimoto H, Nagayama C, Sugino E and Hibino S 1997 *J. Org. Chem.* **62** 2535; (b) Sakamoto T, Nagano T, Kondo Y and Yamanaka H 1988 *Chem. Pharm. Bull.* **36** 2248
9. (a) Sechi M, Derudas M, Dallochio R, Dessí A, Bacchi A, Sannia L, Carta F, Palomba M, Ragab O, Chan C, Shoemaker R, Sei S, Dayam R and Neamati N 2004 *J. Med. Chem.* **47** 5298; (b) Tsotinis A, Afroudakis P A, Davidson K, Prashar A and Sugden D 2007 *J. Med. Chem.* **50** 6436
10. Sonogashira K, Tohda Y and Hagihara N 1975 *Tetrahedron Lett.* **16** 4467
11. Marchal E, Uriac P, Legouin B, Toupet L and van de Weghe P 2007 *Tetrahedron* **63** 9979
12. Somei M, Sayama S, Naka K, Shinmoto K and Yamada F 2007 *Heterocycles* **73** 537
13. Travis B R, Sivakumar M, Hollist G O and Borhan B 2003 *Org. Lett.* **5** 1031
14. (a) Alley M C, Scudiero D A, Monks A, Hursey M L, Czerwinski M J, Fine D L, Abbott J G M, Shoemaker R H and Boyd M R 1988 *Cancer Res.* **48** 589; (b) Mossman T 1983 *J. Immunol. Methods* **65** 55
15. Williams D H, Stephens E, O'Brien D P and Zhou M 2004 *Angew. Chem. Int. Ed.* **43** 6596
16. (a) Morris G M, Huey R, Lindstrom W, Sanner M F, Belew R K, Goodsell D S and Olson A J 2009 *J. Comput. Chem.* **30** 2785; (b) Sanner M F 1999 *J. Mol. Graphics Mod.* **17** 57
17. Wu S, Vossius S, Rahmouni S, Miletic A V, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T and Tautz L 2009 *J. Med. Chem.* **52** 6716